Related Experiment Video
Updated: May 19, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
Youngwoon Kim1, Ka Young Kim, Su Hyun Lee
1Division of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea.
Abstract:
We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when free kappa light chains were noticeably reduced in the serum. After discontinuation of bortezomib, liver enzymes recovered gradually to baseline. Then, the patient was started on a thalidomide-containing regimen, which he was able to tolerate well. The patient achieved complete remission prior to autologous stem cell transplantation (ASCT). The patient underwent ASCT without occurrence of further liver toxicity.
Related Concept Videos
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Risk factors
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug toxicity: Drug–Drug Interaction
Drug Toxicity: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...